RxDoctor Payments DataLook up a doctor →

Edward Maa, MD

Neurological Surgery · Denver, CONPI 1053426643

Payments from drug & device makers

$165,028in general payments, 2019–2025

Across 1,118 payments — averaging $147.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$56K
  • UCB, Inc.$20K
  • SK Life Science, Inc.$18K
  • Livanova USA, Inc.$17K
  • Jazz Pharmaceuticals Inc.$16K
  • Neurelis, Inc.$13K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$43,79327%
  • Speaking & faculty fees$83,85151%
  • Travel & lodging$11,2057%
  • Food & beverage$26,15616%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neuropace, Inc.132$55,979
UCB, Inc.102$20,070
SK Life Science, Inc.37$18,343
Livanova USA, Inc.46$17,423
Jazz Pharmaceuticals Inc.35$15,888
Neurelis, Inc.40$13,350
Greenwich Biosciences, Inc.15$9,788
AbbVie(2 entities)140$2,835
Pfizer69$991
Catalyst Pharmaceuticals, Inc.18$791
Bristol Myers Squibb25$633
Eisai Inc.24$626
EMD Serono, Inc.39$569
Novartis33$533
Neurocrine Biosciences, Inc.43$520
Biohaven Pharmaceutical Holding Company Ltd.37$520
Merz Pharmaceuticals, LLC14$421
Teva Pharmaceuticals USA, Inc.11$368
AstraZeneca(2 entities)15$326
Sanofi14$305
Tanabe Pharma America, Inc.12$286
TG Therapeutics, Inc.13$255
Acadia Pharmaceuticals Inc13$239
Argenx US, Inc.10$227
Medtronic6$222
Mallinckrodt Hospital Products Inc.8$209
Amneal Pharmaceuticals LLC12$200
Genentech USA, Inc.8$199
Sunovion Pharmaceuticals Inc.13$199
Lilly USA, LLC13$197
Amgen7$178
Boston Scientific7$169
Abbott6$153
Biogen13$136
Upsher-smith Laboratories LLC7$130
Axsome Therapeutics, Inc.5$129
Lundbeck LLC6$129
GRT US Holding, Inc.9$129
Octapharma USA, Inc.6$128
CSL Behring4$90
Banner Life Sciences, LLC3$81
MDD US Operations, LLC4$80
Immedica Pharma US, Inc.2$78
Collegium Pharmaceutical, Inc.4$77
Acorda Therapeutics, Inc3$73
Kyowa Kirin, Inc.3$66
Cadwell Industries, Inc1$66
Scilex Pharmaceuticals Inc.4$65
ANI Pharmaceuticals, Inc.3$64
Impel Pharmaceuticals Inc.3$59
Alnylam Pharmaceuticals Inc.2$55
Grifols USA, LLC2$50
Springworks Therapeutics, Inc.2$49
Sumitomo Pharma America, Inc.3$41
Otsuka America Pharmaceutical, Inc.2$34
Vanda Pharmaceuticals Inc.1$32
Avanir Pharmaceuticals, Inc.2$29
Supernus Pharmaceuticals, Inc.2$28
Avion Pharmaceuticals1$26
Harmony Biosciences LLC1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$165,028 in reported general payments places this provider in the 85th percentile of 149 neurological surgery providers in Colorado.

See all neurological surgery providers in Colorado

Medicare billing

Part B allowed, 2024
$50,343
Medicare patients
92
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam59$163,843
XcopriCenobamate76$138,595
IngrezzaValbenazine Tosylate11$94,770
Nurtec OdtRimegepant Sulfate41$75,384
AptiomEslicarbazepine Acetate39$66,956
OnfiClobazam27$66,900
Lamictal XrLamotrigine25$50,268
EpidiolexCannabidiol (Cbd)11$49,370
FycompaPerampanel34$46,420
LamictalLamotrigine19$43,650
ZonegranZonisamide14$30,068
ValtocoDiazepam28$27,143
VimpatLacosamide13$21,799
Lacosamide87$20,426
NuedextaDextromethorphan Hbr/Quinidine11$20,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$20,070$204,35998 claims
SK Life Science, Inc.Xcopri$18,343$138,59576 claims
Neurocrine Biosciences, Inc.Ingrezza$520$94,77011 claims
PfizerNurtec Odt$991$75,38441 claims
Sunovion Pharmaceuticals Inc.Aptiom$199$66,95639 claims
Lundbeck LLCOnfi$129$66,90027 claims
Eisai Inc.Fycompa$626$46,42034 claims
Neurelis, Inc.Valtoco$13,350$27,14328 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29$20,08111 claims
AbbVieQulipta$2,835$11,30111 claims
Upsher-smith Laboratories LLCTopiramate$130$19511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 149 neurological surgery providers in Colorado.

Other neurological surgery in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →